Second candidate from Tenvie’s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV108 in healthy volunteers Preliminary ...

The 37-year-old Lancaster man was sentenced to 14 years and six months in federal prison after he pleaded guilty to ...

CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...

Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear ...

SAN DIEGO -- Half of heavily pretreated patients with platinum-refractory ovarian cancer (PROC) responded to an ...

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm” or the "Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...

This approval provides patients with a new generic option for the folate analog metabolic inhibitor, which is used to treat ...

This episode focuses on long-acting interleukin (IL)-13 biologics and what less frequent dosing could mean for efficacy, ...

A Chinese crackdown on fentanyl-making ingredients could be fueling the resurgence of carfentanil, a chemical so powerful, a ...